Savara (NASDAQ:SVRA) Receives Buy Rating from HC Wainwright

Savara (NASDAQ:SVRA - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 110.16% from the stock's previous close. HC Wainwright also issued estimates for Savara's Q1 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Several other brokerages have also recently weighed in on SVRA. Wells Fargo & Company began coverage on Savara in a research report on Friday, December 20th. They issued an "overweight" rating and a $8.00 price target for the company. JMP Securities reissued a "market outperform" rating and issued a $9.00 price target on shares of Savara in a report on Thursday, December 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.83.

Savara Stock Up 3.1 %

SVRA stock traded up $0.09 during midday trading on Friday, reaching $2.86. 447,331 shares of the company's stock traded hands, compared to its average volume of 1,316,403. Savara has a 52 week low of $2.26 and a 52 week high of $5.34. The company has a market cap of $489.97 million, a price-to-earnings ratio of -6.66 and a beta of 0.60. The firm's fifty day moving average price is $2.72 and its 200-day moving average price is $3.24. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million during the quarter. As a group, sell-side analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its stake in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock valued at $191,000 after purchasing an additional 3,706 shares during the period. Altium Capital Management LLC increased its holdings in Savara by 0.3% in the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock worth $4,848,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after purchasing an additional 4,732 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Savara by 13.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after buying an additional 5,236 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Savara by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after purchasing an additional 5,450 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.